Source: MARKETWIRE

Press Release: Cornerstone Therapeutics : Cornerstone Therapeutics Inc. Stockholders Approve Merger

CARY, NC--(Marketwired - Feb 3, 2014) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) (the "Company" or "Cornerstone"), a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, today announced that its stockholders have approved, at a special stockholder meeting held today, the previously announced merger agreement, under which Chiesi Farmaceutici S.p.A. ("Chiesi") will acquire all of the outstanding common shares of Cornerstone for $9.50 per share in cash.

Read full article »
Est. Annual Revenue
$100-500M
Est. Employees
100-250
Craig  Collard 's photo - CEO of Cornerstone Therapeutics, Inc.

CEO

Craig Collard

CEO Approval Rating

70/100

Read more